According to a study published in the January issue of the journal Foot & Ankle International, treatment with incobotulinumtoxinA (IBTA) may help improve foot function and pain for patients with plantar fasciitis. 

The researchers conducted a randomized, double-blinded, placebo-controlled trial of 50 patients with plantar fasciitis who received an injection of either IBTA (n = 25) or saline (n = 25) in the affected foot. At 6-month follow-up, they found that mean Foot and Ankle Ability Measures increased from 36.3 to 73.8 in the IBTA cohort and from 35.9 to 40.9 in the placebo cohort. In addition, mean pain score decreased from 7.2 to 3.6 in the IBTA group and from 8.4 to 7.9 in the placebo group. At 12-month follow-up, the IBTA group maintained significantly better function and pain than the placebo group, and no patients in the IBTA group and 3 patients in the placebo group had undergone surgery for recalcitrant plantar fasciitis. Learn more...